Letroman

Letrozole, the active ingredient in Letroman, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is employed in the treatment of estrogen receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for metastatic disease. The medication is manufactured in the European Union and conforms to EU regulatory standards.

GNH USA supplies Letroman as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, proper documentation, and timely delivery across global markets.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer.

- Early‑stage estrogen receptor‑positive breast cancer: provides adjuvant therapy to reduce recurrence risk. - Metastatic estrogen receptor‑positive breast cancer: helps control disease progression in postmenopausal patients. - Hormone‑responsive breast cancer in postmenopausal women: used as part of endocrine treatment regimens.

Letrozole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures. - Liver dysfunction: elevated transaminases or hepatitis. - Cardiovascular events: rare cases of thromboembolism or stroke.

When prescribing Letrozole, clinicians should consider several safety precautions to minimize risk.

- Pregnancy contraindication: drug is category X and must not be used during pregnancy. - Breastfeeding avoidance: not recommended for nursing mothers due to potential infant exposure. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: evaluate hepatic enzymes before initiating therapy. - Drug interactions review: check for concomitant medications that may affect aromatase activity. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma levels. - Tamoxifen: concurrent use may diminish therapeutic benefit of both agents.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase letrozole concentrations. - Antidepressants (e.g., SSRIs): potential modest effect on estrogen metabolism. - Hormone replacement therapy: may counteract letrozole’s estrogen‑lowering action. - Cholestyramine or other bile‑acid sequestrants: may lower absorption of letrozole.